For the quarter ending 2025-09-30, GOVX had $1,915,135 increase in cash & cash equivalents over the period. -$6,212,115 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,318,914 | -10,727,434 |
| Depreciation expense | 16,802 | 33,724 |
| Stock-based compensation expense | 277,546 | 585,484 |
| Government contract receivable | -532,771 | -126,638 |
| Prepaid expenses and other current assets | -664 | -259,618 |
| Other assets | 15,937 | 0 |
| Accounts payable and accrued expenses | -705,047 | -578,108 |
| Total adjustments | 106,799 | 427,356 |
| Net cash used in operating activities | -6,212,115 | -10,300,078 |
| Purchase of equipment | 0 | 27,612 |
| Net cash used in investing activities | 0 | -27,612 |
| Net proceeds from issuance of notes payable related parties | 0 | 0 |
| Repayment of notes payable related parties | 0 | - |
| Net proceeds from sale of common stock and warrants | 7,971,250 | 7,914,402 |
| Net proceeds from warrant exercises | 156,000 | 209 |
| Net cash provided by financing activities | 8,127,250 | 7,914,611 |
| Net increase (decrease) in cash and cash equivalents | 1,915,135 | -2,413,079 |
| Cash and cash equivalents at beginning of period | 5,506,941 | - |
| Cash and cash equivalents at end of period | 5,008,997 | - |
GeoVax Labs, Inc. (GOVX)
GeoVax Labs, Inc. (GOVX)